Biodexa Pharmaceuticals Return On Tangible Equity 2015-2024 | BDRX

Biodexa Pharmaceuticals return on tangible equity from 2015 to 2024. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.

Biodexa Pharmaceuticals Return On Tangible Equity 2015-2024 | BDRX

Biodexa Pharmaceuticals return on tangible equity from 2015 to 2024. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$147B
Gilead Sciences (GILD)$116B
Bristol Myers Squibb (BMY)$115.8B
Vertex Pharmaceuticals (VRTX)$110.2B
CSL (CSLLY)$81.9B
Regeneron Pharmaceuticals (REGN)$74.7B
GSK (GSK)$69.3B
Argenex SE (ARGX)$38.6B
Alnylam Pharmaceuticals (ALNY)$34.4B
BioNTech SE (BNTX)$27.6B
Illumina (ILMN)$22.3B
BeiGene (ONC)$21.7B
Biogen (BIIB)$20.8B
Moderna (MRNA)$14.8B
Insmed (INSM)$14B
Incyte (INCY)$13.9B
Genmab (GMAB)$13.9B
Genmab (GNMSF)$13.9B
Intra-Cellular Therapies (ITCI)$13.5B
Bio-Techne Corp (TECH)$12.5B
BioMarin Pharmaceutical (BMRN)$11.8B
Sarepta Therapeutics (SRPT)$11.1B
Vaxcyte (PCVX)$10.8B
QIAGEN (QGEN)$10.8B
Exact Sciences (EXAS)$10.1B
Swedish Orphan Biovitrum (BIOVF)$10.1B
Bio-Rad Laboratories (BIO.B)$9.8B
Exelixis (EXEL)$9.4B
Repligen (RGEN)$9.3B
Roivant Sciences (ROIV)$8.1B